Loading...
•
Mar 31, 2022
Essa Pharma Q2 2022 Earnings Report
Provided a corporate update and reported financial results for the fiscal second quarter.
Key Takeaways
ESSA Pharma reported its financial results for the fiscal second quarter ended March 31, 2022. The company's cash position is expected to be sufficient to fund current and planned operations through 2024.
Continued to dose patients in Phase 1 monotherapy study of EPI-7386.
Expect to present a clinical update on the monotherapy trial in the first half of 2022.
Several clinical collaborations are underway investigating the potential clinical benefit of EPI-7386 in combination with approved second-generation antiandrogens.
Company-sponsored Phase 1/2 study of EPI-7386 in combination with enzalutamide in mCRPC patients who have not yet been treated with second-generation antiandrogen therapies.
Essa Pharma
Essa Pharma
Forward Guidance
ESSA Pharma expects to provide a clinical update on the Phase 1a dose escalation study in the first half of 2022 and believes its cash position is sufficient to fund operations through 2024.
Positive Outlook
- Expect to provide a clinical update on the Phase 1a dose escalation study in the first half of 2022.
- The potential clinical benefit of EPI-7386 in combination with approved second-generation antiandrogens.
- The accuracy of ESSA’s financial projections.
- Obtaining positive results of clinical trials.
- Obtaining necessary regulatory approvals.
Challenges Ahead
- Risks and uncertainties related to future events.
- Uncertainties related to ESSA’s ability to control or predict.
- ESSA’s actual results, performance or achievements to be materially different from those expressed or implied.
- Significant medical, scientific, business, economic, competitive, political and social uncertainties and contingencies.
- General business, market and economic conditions.